Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Gerstein, Hertzel C.; Riddle, Matthew C.; Kendall, David M.; Cohen, Robert M.; Goland, Robin; Feinglos, Mark N.; Kirk, Julienne K.; Hamilton, Bruce P.; Ismail‐Beigi, Faramarz; Feeney, Patricia

doi:10.1016/j.amjcard.2007.03.004

Cited by 167 publications

(115 citation statements)

References 17 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Hyperglycemia, insulin resistance, advanced glycation end products, polyol, hexosamine and protein kinase C pathways collectively contribute to the classical pathogenesis of diabetes complications. However, to date, we know that only serum glucose control is not sufficient to overcome the major cardiovascular (CV) events [3,4] . In this regard, novel risk factors including adipokines such as adiponectin, apelin, obestatin, leptin and resistin, chronic inflammation, and the renin-angiotensin-aldosterone system were found to be involved in the pathogenesis of diabetes and its chronic complications [5] .…”

Section: Introductionmentioning

confidence: 99%

Sirtuins as novel players in the pathogenesis of diabetes mellitus

Türkmen

Karagöz

Küçük

2014

WJD

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a systemic and complex disease with micro and macrovascular complications that result from impaired metabolic pathways and genetic susceptibilities. DM has been accepted as an epidemic worldwide during the last two decades. A substantial gap in our knowledge exists regarding the pathophysiology of this metabolic disorder despite the improved diagnostic tools and therapeutic approaches. Sirtuins are a group of NAD + dependent enzymes that are involved in cellular homeostasis due to their deacetylating activity. In the present review, we aimed to discuss the role of associated sirtuins in the pathogenesis and treatment of diabetes mellitus.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Diabetes mellitus; Sirtuins; Hyperglycemia; Hyperlipidemia; Resveratrol Core tip: Diabetes mellitus has been accepted as an epidemic worldwide during the last two decades. Despite the diagnostic tools and therapeutic approaches, the pathophysiology of this metabolic disorder and cellular defensive mechanisms are unknown. The maintenance of cellular homeostasis requires a well-organized network between glucose, amino acid and lipid metabolism. Sirtuins are a group of NAD + dependent proteins that are involved in cellular homeostasis due to their deacetylating activity. Of these, sirtuin 1, -3 and -4 have been the most extensively investigated. In the present review, we aimed to discuss the role of associated sirtuins in glucose and lipid metabolism and in the pathogenesis and treatment of diabetes mellitus.Turkmen K, Karagoz A, Kucuk A. Sirtuins as novel players in the pathogenesis of diabetes mellitus. World J Diabetes 2014; 5(6): 894-900 Available from:

show abstract

Section: Introductionmentioning

confidence: 99%

Sirtuins as novel players in the pathogenesis of diabetes mellitus

Türkmen

Karagöz

Küçük

2014

WJD

View full text Add to dashboard Cite

show abstract

“…Por otro lado, estudios observacionales longitudinales han revelado prevalencias de ECVA en PD de entre 19,4 y 56,1% [16][17][18][19][20][21] . Así, en un estudio longitudinal de 65.651 PD del país vasco, se encontró una prevalencia de patología cardiovascular de 22% en PD de diagnóstico reciente y de 33,0% en PD de larga data 21 .…”

Section: Discussionunclassified

Asociación entre diabetes mellitus y patología cardiovascular en la población adulta de Chile: estudio de la Encuesta Nacional de Salud 2009-2010

et al. 2014

View full text Add to dashboard Cite

“…ACCORD examined the effect of standard versus intensive glucose-lowering strategy in 10,521 patients with type 2 diabetes and further cardiovascular risk factors or cardiovascular disease (7). At the beginning of the trial, all participants were provided with glucose-monitoring equipment.…”

Section: Accordmentioning

confidence: 99%

“…Individuals in the intensive group receiving insulin were encouraged to take SMBG readings 4-8 times daily ($2 premeal and 2 postmeal) with an additional periodic 0300 h test, while noninsulin-treated patients were advised to perform $2 readings daily (or 4 times daily if their SMBG levels were greater than target). Patients were encouraged to adjust doses every 4 days based on SMBG readings (7).…”

Section: Accordmentioning

confidence: 99%

Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research

et al. 2015

View full text Add to dashboard Cite

Quality glucose information is a core prerequisite for successful diabetes management. It enables professionals and people with diabetes to make medically relevant decisions on therapy. Details of glucose profile information beyond HbA 1c have been largely derived from self-monitoring of blood glucose (SMBG). Given the evidence base demonstrating the benefits of SMBG, its routine use is recommended for diabetes management and therapy by many international and regional guidelines (1-3). Today, SMBG is considered an important aspect of the management of glycemic control (3,4). Glucose information of high quality, considering the products used and the processes conducted, is also needed in clinical research in order to gain new evidence and insights on effective treatment strategies in diabetes. SMBG is widely and routinely applied in large clinical trials, where it is used to understand the glycemic state, to enhance awareness of the effects of lifestyle modification and the adaptation of treatment including insulin titration, and to enable documentation of intraday pre-and postprandial glucose excursions (glycemic variability) and the subsequent statistical analysis of this and the confirmation of hypoglycemic episodes. Examples of recent studies that used SMBG are Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial, Action to Control Cardiovascular Risk in Diabetes (ACCORD), and, from earlier times, the Diabetes Control and Complications Trial (DCCT) (5-8). Indeed, SMBG is now applied in most studies of glucoselowering agents, including glucagon-like peptide 1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT2) inhibitor studies.Reliable glucose information requires a clear definition as part of the study design and protocol, not least to ensure replication of the methodology. Interpretation and comparison of study results may be affected if SMBG methods and results are addressed inconsistently. With regard to the interpretation of outcomes of studies, reporting of SMBG in publications should be of the highest qualitydaccurate, precise, reliable, and reproducible. In many publications, however, relevant details of the SMBG measures are lacking or are incomplete. Therefore, the interpretation of study results may be hampered, reliability of study results may be compromised, and repetition of trials may become necessary.This consensus publication not only aims to summarize learnings from previous clinical studies about the use and reporting of SMBG but also proposes recommendations for the description of the performance and reporting of SMBG in future clinical study protocols and related publications.Clinical trials aim at expanding knowledge and evidence. One major principle of Good Clinical Practice is to conduct clinical studies at a quality standard that provides the highest level of safety for the study participants but also avoids a potentially unnecessary burden on participants by inefficient repetition of the experiments with "human beings" to answer a clinical/scientific qu...

show abstract

Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Cited by 167 publications

References 17 publications

Sirtuins as novel players in the pathogenesis of diabetes mellitus

Sirtuins as novel players in the pathogenesis of diabetes mellitus

Asociación entre diabetes mellitus y patología cardiovascular en la población adulta de Chile: estudio de la Encuesta Nacional de Salud 2009-2010

Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research

Contact Info

Product

Resources

About